Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis.
about
Oral budesonide for induction of remission in ulcerative colitisOral budesonide for induction of remission in ulcerative colitisHistologic scoring indices for evaluation of disease activity in ulcerative colitis.Budesonide in the treatment of inflammatory bowel disease.Budesonide MMX(®): a review of its use in patients with mild to moderate ulcerative colitis.Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis.Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity.Systemic glucocorticoid therapy and adrenal insufficiency in adults: A systematic review.Long-term safety and efficacy of budesonide in the treatment of ulcerative colitisOnce-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.Oral locally active steroids in inflammatory bowel disease.Second-generation corticosteroids for the treatment of Crohn's disease and ulcerative colitis: more effective and less side effects?Recent developments in the treatment of inflammatory bowel disease.Novel extended release budesonide formulation for treatment of ulcerative colitis.The role of Budesonide-MMX in active ulcerative colitis.Steroid use in Crohn's disease.Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis.Low bioavailability steroids in inflammatory bowel disease: an old chestnut or a whole new ballgame?New Applications for Traditional Drugs in Inflammatory Bowel Disease: What Do Cochrane Reviews Tell Us?Approach to a Child with Colitis.Budesonide for the treatment of ulcerative colitis.Systematic review: second-generation vs. conventional corticosteroids for induction of remission in ulcerative colitis.The problem of adherence to therapy in ulcerative colitis and the potential utility of multi-matrix system (MMX) technology.Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis.3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial.MMX® technology and its applications in gastrointestinal diseases.Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies.Development and evaluation of a novel pellet-based tablet system for potential colon delivery of budesonide.Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?Recent advances in the management of distal ulcerative colitis.Topical therapy is underused in patients with ulcerative colitis.Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial.Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis.Mechanisms and management of growth impairment in children affected by inflammatory bowel disease
P2860
Q24186368-279F9355-30C3-43A1-A787-D670FC12DEB9Q24234633-120006C6-4F51-4FED-8830-F42D849716BFQ30234366-48D9094E-7B30-4B83-8A08-38B95EE3717EQ34203594-5B0B0DEE-AD1F-4D75-B97C-A52FB197B650Q34474024-278F3C99-941D-465F-9AA4-507DA64F2A4CQ36531674-568D9B8A-9579-4A29-AB83-B12ED397CB4FQ36659176-DB428C92-C526-4AC4-A1D6-422A5D66E24EQ37180423-7ACD9A17-3021-40FF-BB6A-081B2FE40784Q37577773-DC78281E-51D5-41D8-9AA5-8DA3D4D9F260Q37600339-49DE8FC7-AF84-407A-B7DF-B37C4B57CB67Q38025531-C84C70CD-B82B-40F0-BDED-FABDD1D11A30Q38026396-7D1DBD01-3DC4-475E-89C6-B91ACD30E15BQ38082550-99DF05BD-E86D-42E0-9412-42BE3540757AQ38161988-CFF48756-E956-4982-9AB3-BF3DEFA90E5AQ38185703-7E7254EF-1E57-488D-80B7-D479FF1F656FQ38188477-AB0B4DF4-AD0A-4D42-AEBA-9EA2BE70FE1FQ38196945-44F92FFA-E71E-4432-98F4-E64A7473AAE4Q38216510-9FE0E219-32F6-421E-BF88-4BF22043B1C8Q38625992-1DFB3E4A-E262-4ADB-8260-FCA7E09AED04Q38808872-D2CB4A3B-4E7B-4200-B704-C079A7FC4F8AQ38828972-C67066AA-7AD6-453B-91DD-B785EFB56202Q38960072-8C39A800-9E59-45D4-9E1C-2AE7872915DCQ38996677-D2AA06CC-955E-438D-82BD-BBF9B768A7CCQ39251794-4FDD004C-64CF-489F-97C7-8282E84618FCQ39977343-8BBA2906-35F6-49FE-80A6-9595DD6703CAQ40095211-F759FFEA-F704-48A2-BDE0-5F4F2E00ECE4Q41582729-7325B3CF-EE58-4930-BFA1-82E067AE7CB4Q42152164-F512026D-BF2C-405E-B660-6D5C3EA30ECFQ42695266-FCBFA576-79A2-4DA1-8FFD-6A24EE573972Q42730491-5DD5679E-B653-4ADE-A17C-25154E9D594FQ44237715-EDBB3646-04F0-41CC-A0C0-1244F1CD5E0FQ46934021-C7458412-81C8-40F4-B338-1404002B4CC4Q47958039-C397D782-9930-4DF9-9157-D6CDCFC0014FQ57451004-E4B8776C-A065-4A17-A990-3276ACD41CCA
P2860
Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Clinical trial: Preliminary ef ...... left-sided ulcerative colitis.
@en
Clinical trial: Preliminary ef ...... left-sided ulcerative colitis.
@nl
type
label
Clinical trial: Preliminary ef ...... left-sided ulcerative colitis.
@en
Clinical trial: Preliminary ef ...... left-sided ulcerative colitis.
@nl
prefLabel
Clinical trial: Preliminary ef ...... left-sided ulcerative colitis.
@en
Clinical trial: Preliminary ef ...... left-sided ulcerative colitis.
@nl
P2093
P2860
P1476
Clinical trial: Preliminary ef ...... left-sided ulcerative colitis.
@en
P2093
A F D Di Stefano
A Lavergne-Slove
G R D'Haens
P Vergauwe
P2860
P304
P356
10.1016/J.CROHNS.2009.09.007
P577
2009-10-24T00:00:00Z